{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T15:40:06Z","timestamp":1752075606717,"version":"3.41.2"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"DOI":"10.7759\/cureus.87545","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T15:02:59Z","timestamp":1752073379000},"source":"Crossref","is-referenced-by-count":0,"title":["Xylazine Withdrawal: A Case Report From the Intensive Care Unit to the Medical Ward"],"prefix":"10.7759","author":[{"given":"Hsien Yi","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrus","family":"Nensey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2303120","article-title":"Xylazine \u2014 Medical and public health imperatives","volume":"388","author":"Gupta R","year":"2023","unstructured":"Gupta R, Holtgrave DR, Ashburn MA. Xylazine \u2014 Medical and public health imperatives. N Engl J Med. 2023, 388:2209-12. 10.1056\/NEJMp2303120","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36864","article-title":"Xylazine in the opioid epidemic: A systematic review of case reports and clinical implications","volume":"15","author":"Ayub S","year":"2023","unstructured":"Ayub S, Parnia S, Poddar K, et al.. Xylazine in the opioid epidemic: A systematic review of case reports and clinical implications. Cureus. 2023, 15:e36864. 10.7759\/cureus.36864","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001423","article-title":"Withdrawal signs and symptoms among patients positive for fentanyl with and without xylazine","volume":"19","author":"Alexander R","year":"2025","unstructured":"Alexander R, Agwuncha C, Wilson C, Schrecker J, Holt A, Heltsley R. Withdrawal signs and symptoms among patients positive for fentanyl with and without xylazine. J Addict Med. 2025, 19:202-7. 10.1097\/ADM.0000000000001423","journal-title":"J Addict Med"},{"key":"ref4","unstructured":"U.S. Food and Drug Administration. Lacosamide (Vimpat) [Prescribing Information]. (2021). Accessed. May 15, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/022253s049,022254s039,022255s031lbl.pdf."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.712717","article-title":"Clinical efficacy and safety of lacosamide as an adjunctive treatment in adults with refractory epilepsy","volume":"12","author":"Hou L","year":"2021","unstructured":"Hou L, Peng B, Zhang D, et al.. Clinical efficacy and safety of lacosamide as an adjunctive treatment in adults with refractory epilepsy. Front Neurol. 2021, 12:712717. 10.3389\/fneur.2021.712717","journal-title":"Front Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/20503121251348068","article-title":"The xylazine-fentanyl nexus: A public health emergency","volume":"13","author":"Sandhu KS","year":"2023","unstructured":"Sandhu KS, Kumar S, Garg K, et al.. The xylazine-fentanyl nexus: A public health emergency. SAGE Open Med. 2023, 13:57. 10.1177\/20503121251348068","journal-title":"SAGE Open Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5492\/wjccm.v12.i1.18","article-title":"Clonidine use during dexmedetomidine weaning: A systematic review","volume":"12","author":"Rajendraprasad S","year":"2023","unstructured":"Rajendraprasad S, Wheeler M, Wieruszewski E, et al.. Clonidine use during dexmedetomidine weaning: A systematic review. World J Crit Care Med. 2023, 12:18-28. 10.5492\/wjccm.v12.i1.18","journal-title":"World J Crit Care Med"},{"key":"ref8","article-title":"Clonidine","author":"Yasaei R","year":"2025","unstructured":"Yasaei R, Saadabadi A. Clonidine. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref9","unstructured":"Best Practices for Management of Xylazine . Accessed. May 15, 2025: https:\/\/penncamp.org\/wp-content\/uploads\/2023\/05\/CAMP-Xylazine-Best-Practices-1.pdf."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.205","article-title":"Mechanisms of the gabapentinoids and \u03b1 2 \u03b4-1 calcium channel subunit in neuropathic pain","volume":"4","author":"Patel R","year":"2016","unstructured":"Patel R, Dickenson AH. Mechanisms of the gabapentinoids and \u03b1 2 \u03b4-1 calcium channel subunit in neuropathic pain. Pharmacol Res Perspect. 2016, 4:e00205. 10.1002\/prp2.205","journal-title":"Pharmacol Res Perspect"},{"key":"ref11","article-title":"Quetiapine","author":"Maan JS","year":"2023","unstructured":"Maan JS, Ershadi M, Khan I, Saadabadi A. Quetiapine. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref12","unstructured":"All About Xylazine. (2023). Accessed. May 15, 2025: https:\/\/penncamp.org\/education\/the-risk-of-xylazine\/."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/370667-xylazine-withdrawal-a-case-report-from-the-intensive-care-unit-to-the-medical-ward","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T15:03:00Z","timestamp":1752073380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/370667-xylazine-withdrawal-a-case-report-from-the-intensive-care-unit-to-the-medical-ward"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.87545","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,8]]}}}